Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

PORTLAND, OR, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- The global anti-obesity drugs market, valued at $1,605.36 million in 2022, is projected to reach $4,439.34 million by 2032, expanding ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.